Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.9 pts more than Nifty Smallcap 250 and 7.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma Limited has submitted its quarterly financial results for the three months ended December 31, 2025 to the NSE. The announcement is a standard regulatory filing notifying the exchange that the results have been filed. Detailed figures such as revenue, profit after tax, margins, and auditor observations are not included in this headline filing. Investors will need to review the full results document or the company's investor presentation for actual performance numbers. No comparative metrics or guidance has been provided in this particular notification.
This is a routine compliance filing and is not directly price-moving on its own. The actual market reaction will depend on the numbers in the detailed results — particularly revenue growth, profit margins, and any forward guidance shared alongside the results.